Hemiretinal vein occlusion, often abbreviated HRVO, is a blockage that affects roughly half of the retinal venous drainage in one eye, causing sudden, painless vision loss on the affected side. It sits in an unusual middle ground between the two better-known forms of retinal vein occlusion, and that in-between status shapes everything from how it behaves clinically to how it responds to treatment. Because HRVO is relatively rare, making up less than one percent of all retinal vein occlusions in large datasets, it tends to receive less attention than its counterparts, but it still demands prompt evaluation and management.
How HRVO Fits Among Retinal Vein Occlusions
Retinal vein occlusion is classified by the zone of retinal vein drainage that gets blocked. A central retinal vein occlusion (CRVO) involves the main trunk vein where it exits the eye through the optic nerve head, affecting the entire retina. A branch retinal vein occlusion (BRVO) blocks a smaller downstream branch, usually at a point where an artery crosses over a vein, affecting one quadrant or less of the retina. HRVO falls between these two: it blocks one of the two major trunks of the central retinal vein before they merge, so about half the retina loses its venous outflow.1PubMed Central. A narrative review on the association of high intraocular pressure and glaucoma in patients with retinal vein occlusion
The anatomy behind this split matters. In many people, the central retinal vein forms from two main tributaries that join together either on the optic disc or just behind it. If one of those tributaries gets compressed or clotted before it merges with the other, blood backs up in the half of the retina that tributary drains. On a clinical exam, the pattern is distinctive: hemorrhages, dilated veins, and swelling spread across roughly the upper or lower half of the retina, rather than covering the whole thing (as in CRVO) or just one sector (as in BRVO).
Why It Happens
The underlying mechanism is similar to what drives other retinal vein occlusions. At the optic nerve head, the central retinal artery and vein share a tight connective-tissue sheath. When the arterial wall stiffens and thickens from arteriosclerosis, it can squeeze the thin-walled vein against the rigid surrounding tissue, slowing blood flow and promoting clot formation.2Journal of Thrombosis and Haemostasis. Retinal vein thrombosis: pathogenesis and management In HRVO specifically, this compression happens at the level of one of the two venous trunks before they merge, which is why only half the retina is affected.
Sometimes the trigger is an anatomical quirk rather than age-related vascular disease. One reported case in a 24-year-old involved an abnormal branching pattern of the central retinal artery that wrapped tightly around one of the venous trunks, physically compressing it at the disc. The combination of vessel-wall damage, turbulent flow, and direct compression was enough to cause the occlusion without the usual cardiovascular risk factors.3PubMed Central. Central retinal vein occlusion resulting from anomalous retinal vascular anatomy in a 24-year-old man Cases like these are unusual, but they illustrate that vascular anatomy alone can set the stage.
For most people, though, the systemic risk factors are the familiar cardiovascular ones: high blood pressure, diabetes, high cholesterol, and smoking. These conditions accelerate the arterial wall changes that compress the vein. Elevated eye pressure (intraocular pressure) and glaucoma are also associated with retinal vein occlusions across all subtypes.
How Rare Is It
HRVO is uncommon compared with BRVO and CRVO. A large study characterizing retinal vein occlusions found that HRVO accounted for just 0.9% of all cases.4PubMed Central. Hemi-retinal vein occlusion: Characterizing a rare retinal vasculopathy To put that in perspective, for every HRVO case in that dataset, there were more than 100 cases of other retinal vein occlusion types combined. In a major case-control study, researchers were able to identify only 79 patients with HRVO across five clinical centers, compared with 258 CRVO patients and 270 BRVO patients over the same period.5PubMed. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study
This rarity creates a practical problem: HRVO gets fewer dedicated clinical trials. Much of what we know about treating it comes from studies that enrolled HRVO patients alongside CRVO patients, then analyzed the HRVO subgroup separately. The evidence base is solid enough to guide treatment, but it is thinner than what exists for the more common types.
What You See and Feel
HRVO typically presents as a sudden, painless drop in vision or a visual field defect in one eye. How much vision you lose upfront depends heavily on whether the blockage is ischemic (meaning blood flow is severely cut off, starving the retina of oxygen) or nonischemic (meaning blood flow is reduced but not devastated).
A study tracking the natural history of HRVO found that among nonischemic cases, about three-quarters of patients started with visual acuity of 20/60 or better, and almost all had only mild visual field loss. Among ischemic cases, only about 40% started that well, and just over half had mild field loss; the rest had more serious deficits from the outset.6Retina. HEMICENTRAL RETINAL VEIN OCCLUSION: Natural History of Visual Outcome In other words, the ischemic form hits harder right away, and the visual prognosis tracks closely with how ischemic the eye is at presentation.
Macular edema, the swelling of the central retina responsible for detailed vision, is the main reason vision drops in both forms. Even when the blockage only affects half the retina, fluid can leak into the macula and blur central sight. That is why treatment almost always centers on controlling this swelling.
The Ischemic and Nonischemic Divide
The distinction between ischemic and nonischemic HRVO is not just academic. It determines complication risk and how aggressively you need to be monitored. In nonischemic HRVO, the prognosis for vision is fairly encouraging: among those who started with 20/70 or worse vision, about half showed improvement once macular edema resolved, and only about 6% of those who started with decent vision (20/60 or better) got worse.6Retina. HEMICENTRAL RETINAL VEIN OCCLUSION: Natural History of Visual Outcome
Ischemic HRVO carries a more serious complication: new, abnormal blood vessel growth (neovascularization). When the retina is starved of oxygen, it sends out chemical signals that prompt fragile new vessels to sprout on the retina, optic disc, or iris. These vessels bleed easily and can cause glaucoma. In ischemic HRVO, within the first year, the chance of developing new blood vessels on the retina was about 29%, on the optic disc about 12%, and on the iris about 12%. Neovascular glaucoma, one of the most feared complications, occurred in roughly 5% within six months.7Retina. OCULAR NEOVASCULARIZATION ASSOCIATED WITH CENTRAL AND HEMICENTRAL RETINAL VEIN OCCLUSION These numbers make regular follow-up critical in the months after diagnosis, especially if imaging shows significant ischemia.
Treatment With Anti-VEGF Injections
The mainstay of treatment for HRVO-related macular edema is injections of anti-VEGF drugs directly into the eye. These medications block vascular endothelial growth factor, the chemical signal driving both swelling and abnormal vessel growth. In the SCORE2 trial, a well-known head-to-head comparison, HRVO patients were treated with either aflibercept or bevacizumab. Both drugs reduced macular edema and improved vision, and the treatment response was broadly similar between HRVO and CRVO patients in terms of the amount of visual improvement and the reduction in retinal thickness.8JAMA Ophthalmology. Baseline Characteristics and Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18
One safety concern worth noting: anti-VEGF injections can sometimes raise intraocular pressure. In the SCORE2 trial’s HRVO subgroup, about 10% of patients on aflibercept and about 8% of those on bevacizumab experienced a pressure rise of more than 10 mm Hg above their baseline. Sustained high eye pressure was less common but still occurred.9JAMA Ophthalmology. Intraocular Pressure–Related Events After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial This is manageable but means your eye doctor will check pressures at follow-up visits.
Other Treatment Options
For patients who do not respond well to anti-VEGF therapy or who struggle with the frequency of injections, corticosteroid implants are an alternative. A dexamethasone intravitreal implant has shown efficacy for macular edema associated with retinal vein occlusion and can last several months per injection, reducing the visit burden. The trade-offs include a higher risk of cataract formation and elevated eye pressure, which need monitoring.10Dove Press / Clinical Ophthalmology. Dexamethasone Intravitreal Implant for the Treatment of Macular Edema and Uveitis: A Comprehensive Narrative Review
Laser photocoagulation also plays a role, though its use has shifted over the years. In the ischemic form, laser treatment can be applied to the oxygen-starved retina to reduce the drive for neovascularization. Some studies have also looked at combining laser with anti-VEGF injections. One trial found that patients with retinal vein occlusion, including an HRVO subgroup, who received ranibizumab followed by argon laser photocoagulation had greater improvements in visual acuity and macular edema compared with those treated with ranibizumab alone.11Spandidos Publications / Experimental and Therapeutic Medicine. Clinical efficacy evaluation of treatment of different degrees of retinal vein occlusion with ranibizumab combined with an argon ion laser Laser is not typically a first-line standalone treatment for macular edema anymore, but it remains a useful tool in combination regimens and for managing neovascularization.
How HRVO Compares to BRVO and CRVO in Practice
One of the most clinically relevant findings about HRVO is that it truly behaves as an intermediate condition. The SCORE study (a large multicenter trial) found that at baseline, HRVO eyes fell between BRVO and CRVO eyes in terms of the area of retinal thickening, fluorescein leakage, visual acuity, and central retinal thickness. After treatment, HRVO eyes responded about as well as BRVO eyes and better than CRVO eyes when it came to visual acuity gains.12Archives of Ophthalmology. Baseline Characteristics and Response to Treatment of Participants With Hemiretinal Compared With Branch Retinal or Central Retinal Vein Occlusion in the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study: SCORE Study Report 14
This intermediate positioning matters for prognosis. If you are diagnosed with HRVO rather than CRVO, that is generally a somewhat better starting position. Your initial vision tends to be better, the area of retinal involvement is smaller, and the response to treatment tracks more closely with BRVO outcomes. That said, the ischemic form of HRVO still carries the serious complications discussed above, and the treatment burden (frequent injections, regular monitoring) is comparable across all three subtypes.
Should You Be Tested for Blood-Clotting Disorders
A common question after any retinal vein occlusion diagnosis is whether you should be screened for inherited clotting disorders (thrombophilias). The answer has become more nuanced in recent years. A large meta-analysis found no clear evidence to support routine mass screening for thrombophilia in the overall population of patients with retinal vascular occlusion. In most cases, especially in older adults, traditional cardiovascular risk factors like hypertension and diabetes play the dominant role.13Journal of Thrombosis and Haemostasis. Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta‐analysis
However, the picture may differ in younger patients, where cardiovascular risk factors are less likely to be the whole story. A study from North India looking at patients under 50 with retinal vein occlusion found that classic thrombophilia markers like Factor V Leiden, protein C deficiency, and protein S deficiency were absent in their cohort of 50 patients, and antiphospholipid antibody syndrome and antithrombin deficiency were rare.14Retina. THROMBOPHILIC RISK FACTORS ARE UNCOMMON IN YOUNG PATIENTS WITH RETINAL VEIN OCCLUSION The meta-analysis authors acknowledged that their pooled findings might not apply to younger patients, where inherited clotting conditions could still be relatively more important. They recommended screening on a case-by-case basis, focusing on younger patients without other risk factors, those with a personal or family history of blood clots, or those with autoimmune conditions.13Journal of Thrombosis and Haemostasis. Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta‐analysis
What this means in practice: if you are over 50 and have high blood pressure or diabetes, your doctor will probably focus on optimizing those conditions rather than ordering an exhaustive battery of clotting tests. If you are younger and have no obvious cardiovascular risk factors, a targeted workup for clotting disorders is more reasonable.
Living With the Treatment Burden
Even when treatment works, living with retinal vein occlusion is demanding. Anti-VEGF therapy requires repeated injections and frequent clinic visits, sometimes monthly for an extended period. A review of quality-of-life research in retinal vein occlusion highlighted that this ongoing treatment burden, including the injections themselves, long-term monitoring, and associated costs, remains a significant source of distress for patients.15Ophthalmologica. Quality of Life in Patients with Retinal Vein Occlusion: A Review of the Literature
Interestingly, a cross-sectional study measuring vision-related quality of life found that patients with retinal vein occlusion scored somewhat better on standardized questionnaires than patients with diabetic macular edema or age-related macular degeneration receiving similar injection therapy, though the differences were not statistically significant. Treatment satisfaction was generally high across all groups.16PubMed Central. Quality of Life and Treatment Satisfaction in Patients Receiving Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Cross-Sectional Study This may partly reflect the fact that retinal vein occlusion usually affects one eye and tends to have a reasonable treatment response, especially in the nonischemic form. Nonetheless, the practical reality of repeated eye injections is something patients and doctors need to plan around together.
Newer therapies and longer-acting drug formulations are areas of active research. The hope is that future treatments will extend the interval between injections, easing the logistical and emotional weight of chronic management. For now, the best strategy is to stick with the treatment schedule your retinal specialist recommends, since delays in anti-VEGF therapy can allow macular edema to recur and erode visual gains.
When HRVO Gets Misclassified
One underappreciated issue is that HRVO can be misclassified as either CRVO or BRVO, especially early on when the clinical picture is still evolving. If hemorrhages are extensive, they can obscure the boundary between the affected and unaffected halves of the retina, making the occlusion look like a CRVO. Conversely, if the hemorrhages are relatively contained, a clinician might label it as a large BRVO. The distinction matters because treatment protocols and follow-up schedules differ, and the expected complication rates for ischemic HRVO are different from those for BRVO or CRVO.
Careful examination of the hemorrhage pattern and fluorescein angiography usually sorts this out. In a true HRVO, the hemorrhages and vein dilation follow the distribution of one of the two hemiretinal venous trunks, covering roughly the upper or lower half of the retina rather than a single quadrant or the entire fundus. If you have been told you have a retinal vein occlusion and the classification seems uncertain, asking whether the pattern fits HRVO can be worthwhile, since it may affect your prognosis and monitoring plan.